Aeterna Zentaris: Updated Interim Phase 1 Trial Results for AEZS-108 in Prostate Cancer To Be Presented at Upcoming ASCO GCS Mee

QUÉBEC CITY, Jan. 26, 2012 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced that Jacek Pinski, MD, PhD, Associate Professor of Medicine at the Norris Comprehensive Cancer Center of the University of Southern California, will present updated interim results from a Phase 1 clinical trial in prostate cancer with AEZS-108 (zoptarelin doxorubicin), the Company's targeted cytotoxic luteinizing hormone releasing hormone ("LHRH") analog. The presentation will take place on Thursday, February 2, 2012, during the American Society of Clinical Oncology Genitourinary Cancers Symposium which will be held February 2-4, 2012 in San Francisco.

Poster D3:  "A Phase 1 trial of AEZS-108 in castration - and taxane-resistant prostate cancer ", S.V. Liu, A.V. Schally, T.B. Dorff, D.D. Tsao-Wei, S.G. Groshen, S. Xiong, D. Hawes, D.I. Quinn, Y.C. Tai, N.L. Block, J. Engel, J. K. Pinski
Presenter:   Jacek Pinski, MD, PhD
Session:   General Poster Session A: Prostate Cancer
Date and time:  Thursday, February 2, 2012, 11:45 a.m. - 1:15 p.m. (Pacific)
Venue:   Golden Gate Hall, San Francisco Marriot Marquis


About AEZS-108

AEZS-108 (zoptarelin doxorubicin) represents a new targeting concept in oncology using a hybrid molecule composed of a synthetic peptide carrier and a well-known chemotherapy agent, doxorubicin. AEZS-108 is the first intravenous drug in a clinical study that directs the chemotherapy agent specifically to LHRH-receptor expressing tumors, resulting in more targeted treatment with less damage to healthy tissue. The product has successfully completed Phase 2 studies for the treatment of endometrial and ovarian cancer, and is also in Phase 1/2 trials in prostate and bladder cancer. AEZS-108 has been granted orphan-drug designation by the FDA and orphan medicinal product designation from the EMA for the treatment of ovarian cancer. Aeterna Zentaris owns the worldwide rights to AEZS-108.

About Aeterna Zentaris Inc.

Aeterna Zentaris is a late-stage oncology drug development company currently investigating potential treatments for various cancers including colorectal, multiple myeloma, endometrial, ovarian, prostate and bladder cancer. The Company's innovative approach of "personalized medicine" means tailoring treatments to a patient's specific condition and to unmet medical needs. Aeterna Zentaris' deep pipeline is drawn from its proprietary discovery unit providing the Company with constant and long-term access to state-of-the-art therapeutic options. For more information please visit www.aezsinc.com

SOURCE AETERNA ZENTARIS INC.

Suggested Articles

AbbVie snagged the option to license Harpoon’s anti-BCMA multiple myeloma candidate and the duo added up to six new targets to their discovery deal.

In this week's EuroBiotech Report, Bayer's heart failure drug clears phase 3 test, ABPI calls for more U.K. investment and GHO raises €975 million. 

In our EuroBiotech roundup this week, Azeria raises £32 million, Zealand delays phase 3 readout and Galapagos eyes early 2021 IPF futility analysis.